---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-113463"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T16:49:24.880725+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rigel's fostamatinib misses primary endpoint in Phase 3 COVID-19 trial; p=0.0603

## Summary
- FOCUS Phase 3 trial of fostamatinib in high-risk hospitalized COVID-19 patients did not meet primary endpoint for days on oxygen (p=0.0603).
- Mean days on oxygen were 6.9 for fostamatinib vs 9.0 for placebo; mortality 4 vs 8 deaths (50% reduction, p=0.4521).
- All prespecified secondary endpoints numerically favored fostamatinib, including ordinal scale change to Day 15 (-2.4 vs -1.9, p=0.0428).
- Safety profile consistent with prior experience; no new safety issues; study supported by U.S. Department of Defense.
- Company evaluating next steps in collaboration with partner, U.S. Department of Defense.

## SEC filing metadata
- accession: 0001104659-22-113463
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000110465922113463/0001104659-22-113463-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000110465922113463/tm2229339d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-113463
- JSON: https://secwatch.observer/filing/0001104659-22-113463.json
- Plain text: https://secwatch.observer/filing/0001104659-22-113463.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.